[{"id":"9d2215ee-6fd7-46c1-bce0-de06efcc95e6","acronym":"FOLFIRINOX-R","url":"https://clinicaltrials.gov/study/NCT03828799","created_at":"2021-04-19T19:53:18.354Z","updated_at":"2024-07-02T16:35:19.989Z","phase":"Phase 1/2","brief_title":"Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer","source_id_and_acronym":"NCT03828799 - FOLFIRINOX-R","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" UGT1A1","pipe":" | ","alterations":" RAS mutation • UGT1A1*1*1 • UGT1A1 wild-type","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • UGT1A1*1*1 • UGT1A1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Stivarga (regorafenib) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 12/02/2021","primary_completion_date":" 12/02/2021","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-02-09"},{"id":"d4b8682b-1c56-42e4-a0d8-dc1a45eb1425","acronym":"ENSEMBLE","url":"https://clinicaltrials.gov/study/NCT05646511","created_at":"2022-12-12T15:00:16.382Z","updated_at":"2024-07-02T16:35:46.746Z","phase":"Phase 3","brief_title":"Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE)","source_id_and_acronym":"NCT05646511 - ENSEMBLE","lead_sponsor":"National Cancer Center Hospital East","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1 • UGT1A1 wild-type","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1 • UGT1A1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 608","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2023-05-31"},{"id":"35d33ff5-4c4a-4713-9f95-ecc89a575890","acronym":"","url":"https://clinicaltrials.gov/study/NCT03329183","created_at":"2021-01-18T16:26:22.714Z","updated_at":"2024-07-02T16:37:02.767Z","phase":"Phase 2","brief_title":"High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28","source_id_and_acronym":"NCT03329183","lead_sponsor":"Shanghai Changzheng Hospital","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1 • UGT1A1 wild-type","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1 • UGT1A1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Unknown status","enrollment":" Enrollment 90","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2019-02-15"}]